mAbs vs CAR-T: A Head-to-Head Comparison for CMOs and CSOs

State Of The Art in SLE: For Biotech CMOs and CSOs

This podcast summarizes the therapeutic landscape and the underlying molecular understanding of the causal pathways in lupus. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe [https://www.drugdevelop.com/subscribe?utm_medium=podcast&utm_campaign=CTA_2]

mAbs vs CAR-T: A Head-to-Head Comparison for CMOs and CSOs

CAR-T Illustration. Courtesy New Scientist A recent head-to-head study assessed the comparative effectiveness of different B-cell depletion strategies in patients with autoimmune diseases, specifically comparing protein-based therapies like obinutuzumab (OBI), blinatumomab (BLI), and rituximab (RTX) with cell-based CD19 chimeric antigen receptor (CAR) T-cell therapy. Researchers analyzed lymph node biopsies to assess the extent of B-cell depletion and changes in follicular architecture. They documented that CAR-T was most effective in depleting B cells and disrupting follicular architecture, and concluded that these data indicate potential superiority of CAR-T cell therapies. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe [https://www.drugdevelop.com/subscribe?utm_medium=podcast&utm_campaign=CTA_2]

Type 5 Diabetes: For CMOs and CSOs

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe [https://www.drugdevelop.com/subscribe?utm_medium=podcast&utm_campaign=CTA_2]

B-cell depletion for autoimmune diseases: For Biotech CMOs and CSOs

New B cell depleters in development may offer superior impact on the immune system, durably "reset" the immune system, potentially cure conditions like pre-Type 1 Diabetes and SLE, or allow celiac disease patients to tolerate gluten again. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe [https://www.drugdevelop.com/subscribe?utm_medium=podcast&utm_campaign=CTA_2]

Interleukin-6 and Cardioimmunology: For CMOs and CSOs

This podcast discusses the role of inflammation, specifically interleukin-6 (IL-6) signaling, in cardiovascular diseases (CVD), including atherosclerosis and myocardial infarction (MI). We discuss the therapeutic potential of blocking IL-6 or its receptor (IL-6R) with drugs like tocilizumab and ziltivekimab, highlighting their ability to reduce inflammatory markers, such as C-reactive protein (CRP), and potentially improve patient outcomes in conditions like ST-elevation myocardial infarction (STEMI) and rheumatoid arthritis (RA). The "ZEUS trial" is presented as a significant ongoing study evaluating ziltivekimab's impact on major adverse cardiovascular events in high-risk patients. The podcast balances the potential benefits of these treatments with the complexities and potential side effects of anti-inflammatory therapies, such as an increased risk of infection or gastrointestinal perforation, emphasizing the need for further research and personalized treatment approaches. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe [https://www.drugdevelop.com/subscribe?utm_medium=podcast&utm_campaign=CTA_2]